Business News • PR NewsWire • TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn® Intravenous Formulation to the China Food and Drug Administration

TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn® Intravenous Formulation to the China Food and Drug Administration

TaiGen Biotechnology Announces Submission of New Drug Application for Taigexyn® Intravenous Formulation to the China Food and Drug Administration

TAIPEI, Taiwan, May 30, 2017 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced that it has submitted a New Drug Application (NDA) for the intravenous formulation of Taigexyn® (Nemonoxacin) to the China Food and Drug Administration (CFDA). Taigexyn® is a...

View More : http://www.prnewswire.com/news-releases/taigen-biotechnology-announces-submission-of-new-drug-application-for-taigexyn-i...

Releted News by prnewswire

Glance Enters Marijuana Fintech Market With $1,000,000 Licence to Cannapay Financial Inc.

Le Patient-Family Partner Program harmonise l'engagement du patient par des actions améliorées